Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI).

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2031

Conditions

Breast CancerContrast Enhanced Ultrasound

Interventions

DRUG

Lumason

Up to 4.8mL administered intravenously

Trial Locations (1)

RECRUITING

Penn State Health College of Medicine, Hershey

All Listed Sponsors

lead

Milton S. Hershey Medical Center

OTHER